{"entity":{"id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","aka":[],"tldr":"A phase 2 trial of Temozolomide in glioma & glioblastoma, run by Imvax, active and no longer recruiting.","summary":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma is a phase 2 interventional study registered as NCT04485949 by Imvax, with 99 participants enrolled, started 2023-03-20 and due to reach its primary completion in 2027-01. Interventions recorded: IGV-001 Cell Immunotherapy, Placebo, Standard of Care (SOC): Radiation Therapy and SOC: Temozolomide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04485949","url":"https://clinicaltrials.gov/study/NCT04485949"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04485949","phase":"2","setting":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma","sponsor":"Imvax","enrolled":99,"outcomes":[]},"route":"/trials/nct04485949/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}]}}